|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Affectis Pharmaceuticals AG, of Munich, Germany, closed a C4 million (US$5.2 million) Series B financing round led by EMBL Ventures, of Heidelberg, Germany. The company said proceeds will be used to advance its drug development programs into the clinic for the treatment of depression. Affectis' lead candidate addresses an ion channel associated with depression that has been validated as a possible target to act faster than existing antidepressants with fewer side effects. Along with the financing, Christof Antz, managing partner of EMBL Ventures, will join Affectis' board.
o Affymetrix Inc., of Santa Clara, Calif., launched the GeneChip Globin-Reduction kits ...